Sage Therapeutics: Disappointing Phase III Results Will Be A Burden

About: Sage Therapeutics, Inc. (SAGE)
by: Robert Falcone
This article is exclusive for subscribers.
Robert Falcone
Long-term horizon, value, Deep Value

Sage Therapeutics lost almost 90$/share following news that its oral SAGE-217 failed to meet the primary endpoint in its Phase III study for Major Depressive Disorder.

Some positive outcomes were observed in this study (MOUNTAIN) which may have indicated the selling was overdone.

SAGE-217 is currently in two additional Phase III trials for treatment in MDD, one for postpartum depression, and one for comorbid MDD and insomnia.

Overview of Sage Therapeutics

Sage Therapeutics (SAGE) is a relatively young pharmaceutical company that is working to discover, develop and deliver novel medications for treatment of central nervous system disorders (CNS). The company's